Aim Immunotech Financials
This page shows Aim Immunotech (AIMI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AIM ImmunoTech’s visible business mechanic is funding research and overhead with external capital because revenue remains negligible.
From FY2024 to FY2025, operating loss fell from-$19.8M to-$11.7M even though revenue roughly halved, so the narrower loss came from expense reduction rather than a commercial ramp. The business still was not self-funding: FY2025 financing inflows of$10.4M nearly covered operating cash burn of-$11.0M , meaning cash preservation depended on outside capital, not customers.
By FY2025, negative equity of
With just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Aim Immunotech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aim Immunotech has an operating margin of -13254.6%, meaning the company retains $-13255 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -11630.6% the prior year.
Aim Immunotech's revenue declined 48.2% year-over-year, from $170K to $88K. This contraction results in a growth score of 0/100.
Aim Immunotech carries a low D/E ratio of -0.09, meaning only $-0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.
Aim Immunotech's current ratio of 0.53 is below the typical benchmark, resulting in a score of 5/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Aim Immunotech passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Aim Immunotech generates $0.78 in operating cash flow (-$11.0M OCF vs -$14.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aim Immunotech earns $-14.4 in operating income for every $1 of interest expense (-$11.7M vs $812K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Aim Immunotech generated $88K in revenue in fiscal year 2025. This represents a decrease of 48.2% from the prior year.
Aim Immunotech's EBITDA was -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.3% from the prior year.
Aim Immunotech reported -$14.0M in net income in fiscal year 2025. This represents an increase of 19.4% from the prior year.
Aim Immunotech earned $-8.62 per diluted share (EPS) in fiscal year 2025. This represents an increase of 72.1% from the prior year.
Cash & Balance Sheet
Aim Immunotech held $3.0M in cash against $927K in long-term debt as of fiscal year 2025.
Aim Immunotech had 3M shares outstanding in fiscal year 2025. This represents an increase of 368.5% from the prior year.
Margins & Returns
Aim Immunotech's operating margin was -13254.6% in fiscal year 2025, reflecting core business profitability. This is down 1624.0 percentage points from the prior year.
Aim Immunotech's net profit margin was -15861.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 5673.1 percentage points from the prior year.
Capital Allocation
Aim Immunotech invested $3.9M in research and development in fiscal year 2025. This represents a decrease of 36.7% from the prior year.
AIMI Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21K-19.2% | $26K+4.0% | $25K+56.3% | $16K-64.4% | $45K+28.6% | $35K-30.0% | $50K+25.0% | $40K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.1M+75.1% | $607K-48.3% | $1.2M+8.7% | $1.1M-35.1% | $1.7M+15.8% | $1.4M+25.5% | $1.1M-41.3% | $2.0M |
| SG&A Expenses | $1.9M+4.0% | $1.8M+20.9% | $1.5M-41.6% | $2.5M-39.8% | $4.2M+37.3% | $3.1M+18.8% | $2.6M-32.1% | $3.8M |
| Operating Income | -$3.0M-20.6% | -$2.4M+7.5% | -$2.6M+26.9% | -$3.6M+38.2% | -$5.9M-30.4% | -$4.5M-21.5% | -$3.7M+35.6% | -$5.7M |
| Interest Expense | $391K+164.2% | $148K-0.7% | $149K+20.2% | $124K-6.1% | $132K-34.7% | $202K+12.8% | $179K+148.6% | $72K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.2M-27.1% | -$3.3M-17.5% | -$2.8M+24.6% | -$3.7M+37.9% | -$6.0M-61.3% | -$3.7M-101.5% | -$1.8M+68.4% | -$5.8M |
| EPS (Diluted) | N/A | $1.57+142.7% | $-3.68 | $-0.05 | N/A | $-6.00-100.0% | $-3.00-2400.0% | $-0.12 |
AIMI Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.8M+5.2% | $5.5M+33.1% | $4.1M-33.9% | $6.2M-27.4% | $8.6M-36.6% | $13.6M-13.5% | $15.7M-2.9% | $16.2M |
| Current Assets | $3.3M+28.0% | $2.6M+151.2% | $1.0M-60.3% | $2.6M-38.1% | $4.2M-44.8% | $7.6M-26.9% | $10.4M-8.4% | $11.3M |
| Cash & Equivalents | $3.0M+27.2% | $2.3M+393.1% | $476K-47.0% | $898K-47.2% | $1.7M+85.9% | $915K-74.3% | $3.6M+7.9% | $3.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $7K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $15.6M+34.5% | $11.6M+8.4% | $10.7M+5.6% | $10.1M+1.8% | $9.9M-7.0% | $10.7M+11.1% | $9.6M-15.4% | $11.4M |
| Current Liabilities | $6.2M+53.9% | $4.0M-61.1% | $10.4M+6.4% | $9.8M+2.4% | $9.5M-5.6% | $10.1M+14.2% | $8.8M-10.5% | $9.9M |
| Long-Term Debt | $927K | N/A | $2.7M+14.0% | $2.4M-15.0% | $2.8M+1919.4% | $139K-50.9% | $283K-70.2% | $950K |
| Total Equity | -$9.8M-61.0% | -$6.1M+7.2% | -$6.5M-69.7% | -$3.9M-191.8% | -$1.3M-145.4% | $2.9M-52.3% | $6.1M+26.4% | $4.8M |
| Retained Earnings | -$440.8M-1.0% | -$436.6M-0.8% | -$433.3M-0.6% | -$430.5M-0.9% | -$426.8M-1.4% | -$420.9M-0.9% | -$417.2M-0.4% | -$415.3M |
AIMI Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M+60.9% | -$5.1M-231.7% | -$1.5M+35.2% | -$2.4M+40.3% | -$4.0M-27.2% | -$3.1M-3.4% | -$3.0M+37.5% | -$4.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$4.0M | N/A | N/A | N/A |
| Investing Cash Flow | -$95K-132.1% | $296K-60.7% | $754K-16.0% | $898K-75.8% | $3.7M+1009.0% | $334K-59.6% | $826K+622.8% | -$158K |
| Financing Cash Flow | $2.7M-59.1% | $6.7M+1774.4% | $355K-46.2% | $660K-36.4% | $1.0M+656.9% | $137K-94.4% | $2.4M-13.7% | $2.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AIMI Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -14057.1%-4645.6pp | -9411.5%+1172.5pp | -10584.0%+12034.8pp | -22618.8%-9607.6pp | -13011.1%-185.4pp | -12825.7%-5437.7pp | -7388.0%+6947.0pp | -14335.0% |
| Net Margin | -19881.0%-7250.2pp | -12630.8%-1454.8pp | -11176.0%+11980.3pp | -23156.3%-9896.3pp | -13260.0%-2688.6pp | -10571.4%-6899.4pp | -3672.0%+10870.5pp | -14542.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -127.1%-97.0pp | -30.1%+90.4pp | -120.5% |
| Return on Assets | -72.2%-12.4pp | -59.8%+7.9pp | -67.7%-8.4pp | -59.3%+10.0pp | -69.3%-42.1pp | -27.2%-15.5pp | -11.7%+24.3pp | -35.9% |
| Current Ratio | 0.53-0.1 | 0.64+0.5 | 0.10-0.2 | 0.26-0.2 | 0.44-0.3 | 0.75-0.4 | 1.17+0.0 | 1.14 |
| Debt-to-Equity | -0.09+1.8 | -1.90-1.5 | -0.42+0.2 | -0.62+1.5 | -2.12-2.2 | 0.050.0 | 0.05-0.2 | 0.20 |
| FCF Margin | N/A | N/A | N/A | N/A | -8788.9% | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$9.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Aim Immunotech's annual revenue?
Aim Immunotech (AIMI) reported $88K in total revenue for fiscal year 2025. This represents a -48.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aim Immunotech's revenue growing?
Aim Immunotech (AIMI) revenue declined by 48.2% year-over-year, from $170K to $88K in fiscal year 2025.
Is Aim Immunotech profitable?
No, Aim Immunotech (AIMI) reported a net income of -$14.0M in fiscal year 2025, with a net profit margin of -15861.4%.
What is Aim Immunotech's EBITDA?
Aim Immunotech (AIMI) had EBITDA of -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aim Immunotech have?
As of fiscal year 2025, Aim Immunotech (AIMI) had $3.0M in cash and equivalents against $927K in long-term debt.
What is Aim Immunotech's operating margin?
Aim Immunotech (AIMI) had an operating margin of -13254.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Aim Immunotech's net profit margin?
Aim Immunotech (AIMI) had a net profit margin of -15861.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Aim Immunotech's operating cash flow?
Aim Immunotech (AIMI) generated -$11.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aim Immunotech's total assets?
Aim Immunotech (AIMI) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aim Immunotech spend on research and development?
Aim Immunotech (AIMI) invested $3.9M in research and development during fiscal year 2025.
What is Aim Immunotech's current ratio?
Aim Immunotech (AIMI) had a current ratio of 0.53 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aim Immunotech's debt-to-equity ratio?
Aim Immunotech (AIMI) had a debt-to-equity ratio of -0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aim Immunotech's return on assets (ROA)?
Aim Immunotech (AIMI) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aim Immunotech's cash runway?
Based on fiscal year 2025 data, Aim Immunotech (AIMI) had $3.0M in cash against an annual operating cash burn of $11.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aim Immunotech's debt-to-equity ratio negative or unusual?
Aim Immunotech (AIMI) has negative shareholder equity of -$9.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aim Immunotech's Piotroski F-Score?
Aim Immunotech (AIMI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aim Immunotech's earnings high quality?
Aim Immunotech (AIMI) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aim Immunotech cover its interest payments?
Aim Immunotech (AIMI) has an interest coverage ratio of -14.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aim Immunotech?
Aim Immunotech (AIMI) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.